Zoetis Q3: Strong Osteoarthritis Pain Franchise
Portfolio Pulse from
Zoetis has been given a 'Buy' rating with a target price of $210 per share, driven by strong performance of its osteoarthritis drugs, LIBRELA and SOLENSIA, which saw 97% operational revenue growth. Zoetis projects significant revenue and net income growth for FY24.
November 11, 2024 | 4:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zoetis has been rated as a 'Buy' with a target price of $210, supported by strong growth in its osteoarthritis drugs and positive revenue projections for FY24.
The 'Buy' rating and target price of $210 are based on the strong performance of Zoetis' osteoarthritis drugs, which have shown significant revenue growth. The company's positive revenue and net income projections for FY24 further support the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100